利好！这家公司，深夜大涨

Group 1 - The core point of the news is that Sanofi announced its acquisition of Denaviv Pharmaceuticals for approximately $2.2 billion, aiming to enhance its vaccine product line focused on influenza vaccines [3] - Denaviv Pharmaceuticals' stock price surged over 38% following the acquisition announcement, indicating strong market reaction [2][3] - The acquisition will allow Sanofi to gain access to an already marketed hepatitis B vaccine and an experimental shingles vaccine currently in early human trials, strengthening its position in the adult vaccination market [3] Group 2 - The broader market context shows mixed performance among major U.S. stock indices, with the Dow Jones up 0.14%, the Nasdaq down 0.09%, and the S&P 500 up 0.03% as of the report [1]